共 50 条
- [25] Health-related quality-of-life and treatment satisfaction of individuals with hemophilia A treated with turoctocog alfa pegol (N8-GP): a new recombinant extended half-life FVIII [J]. PATIENT PREFERENCE AND ADHERENCE, 2019, 13 : 497 - 513
- [27] Budget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective [J]. BMC HEALTH SERVICES RESEARCH, 2018, 18
- [28] Predicting Individual Changes in Terminal Half-Life After Switching to Extended Half-Life Concentrates in Patients With Severe Hemophilia [J]. HEMASPHERE, 2022, 6 (04): : E694